BioCentury
ARTICLE | Clinical News

DFMO/sulindac: Phase III started

December 9, 2013 8:00 AM UTC

Cancer Prevention began a double-blind, placebo-controlled, international Phase III trial to compare 750 mg oral eflornithine once daily plus 150 mg oral sulindac once daily vs. eflornithine or sulind...